A new bioluminescent cell-based assay for the detection of alpha-3 acetylcholine receptor antibodies: a multicentre comparison with current methods
9 affiliations
- 1Department of Clinical Immunology, Royal Prince Alfred Hospital, Level 6, Building 77, Vic Block, 50 Missenden Rd. Camperdown, Sydney, NSW Australia
- 2Central Sydney Immunopathology Laboratory, Royal Prince Alfred Hospital, Sydney, Australia
- 3Institute of Academic Medicine, Sydney Local Health District, Sydney, Australia
- 4Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
- 5Second Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
- 6Tzartos NeuroDiagnostics, Athens, Greece
- 7Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
- 8University College London Hospital NHS Trust, London, UK
- 9Neurology Department, Royal Prince Alfred Hospital, Sydney, Australia
Abstract
Autoimmune autonomic ganglionopathy (AAG) is a disorder of the autonomic nervous system associated with autoantibodies against the α3 subunit of the ganglionic acetylcholine receptor (gnACHR). gnACHR antibodies exert their effects via receptor internalisation, but most current gnACHR diagnostic assays only detect antibody binding. Hence, we developed a new bioluminescent cell-based assay (BLIA) to measure internalising gnACHR antibodies. The BLIA was performed by incubating patient sera with live IMR-32 cells that express surface gnACHR. Remaining surface gnACHR was quantified using a novel split luciferase system with NanoBiT conjugated detecting antibodies. The percentage of receptor internalisation was calculated with comparison to cells incubated with reference sera, with > 20% receptor internalisation considered positive for gnACHR antibodies. The BLIA was validated using 46 samples from 20 AAG patients and 203 control samples. Subsequent comparisons to four existing assays were performed: (1) radioimmunoprecipitation assay (RIPA), (2) flow cytometric internalisation assay (FCIA), (3) cell-based assay (CBA-1) where HEK293T cells were transfected with α3β4 gnACHR subunits and (4) optimised CBA-2 with additional transfection of RIC3 and NACHO and incubation with 1 mM nicotine. The BLIA detected gnACHR antibodies with 100% sensitivity and 100% specificity (AUROC = 1.0) with detection of the internalising effects of antibodies to concentrations of < 0.1 pM. There was complete qualitative agreement with CBA-2 (Cohen’s kappa = 1). No statistical difference between these two assays and the RIPA, which had slightly lower sensitivity (98%) and specificity (95%), or the FCIA, which had slightly reduced specificity (95%), was found. CBA-1 had significantly lower sensitivity (69%, p = 0.0003). Overall, the BLIA had perfect clinical sensitivity and specificity in detecting gnACHR antibodies in AAG patients and detection of the functional effects of gnACHR antibodies via internalisation offers a suitable alternative to current assays. Further assessment of its possible role in monitoring disease severity or treatment response is warranted.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s40478-026-02386-9.
Related
- Transplacental transfer of maternal binding and neutralizing antibodies against Respiratory Syncytial Virus – an assay specific comparison
- Territory-based ultrasound assessment for extracranial and vertebrobasilar arterial stenosis and carotid plaque vulnerability: a multicentre comparison with digital subtraction angiography and histopathology
- Sequencing BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma: A Real-World Comparison of CAR T-Cell Therapy and Bispecific Antibodies.
- Comparison of two automated pupillometry indices in patients with acute brain injury: the prospective multicentre LYNX cohort study.
- Development and evaluation of indirect-ELISA based on recombinant nucleoprotein for detection of Ganjam virus (GANV) specific antibodies in small ruminants
BibTeX
@article{stoyanov2026bioluminescent,
title = {{A new bioluminescent cell-based assay for the detection of alpha-3 acetylcholine receptor antibodies: a multicentre comparison with current methods}},
author = {Alex Stoyanov and John Tzartos and Hannah Fox and Maria Pechlivanidou and Peter Bradhurst and Valeria Iodice and Laura Watson and Giacomo Chiaro and Judith M. Spies and Stephen Adelstein and Patrick Waters and Nicolás Urriola},
journal = {Acta Neuropathologica Communications},
year = {2026},
month = aug,
doi = {10.1186/s40478-026-02386-9},
url = {https://doi.org/10.1186/s40478-026-02386-9},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A new bioluminescent cell-based assay for the detection of alpha-3 acetylcholine receptor antibodies: a multicentre comparison with current methods
AU - Alex Stoyanov
AU - John Tzartos
AU - Hannah Fox
AU - Maria Pechlivanidou
AU - Peter Bradhurst
AU - Valeria Iodice
AU - Laura Watson
AU - Giacomo Chiaro
AU - Judith M. Spies
AU - Stephen Adelstein
AU - Patrick Waters
AU - Nicolás Urriola
PY - 2026
DA - 2026/08/08
JO - Acta Neuropathologica Communications
DO - 10.1186/s40478-026-02386-9
UR - https://doi.org/10.1186/s40478-026-02386-9
AB - Autoimmune autonomic ganglionopathy (AAG) is a disorder of the autonomic nervous system associated with autoantibodies against the α3 subunit of the ganglionic acetylcholine receptor (gnACHR). gnACHR antibodies exert their effects via receptor internalisation, but most current gnACHR diagnostic assays only detect antibody binding. Hence, we developed a new bioluminescent cell-based assay (BLIA) to measure internalising gnACHR antibodies. The BLIA was performed by incubating patient sera with live IMR-32 cells that express surface gnACHR. Remaining surface gnACHR was quantified using a novel split luciferase system with NanoBiT conjugated detecting antibodies. The percentage of receptor internalisation was calculated with comparison to cells incubated with reference sera, with > 20% receptor internalisation considered positive for gnACHR antibodies. The BLIA was validated using 46 samples from 20 AAG patients and 203 control samples. Subsequent comparisons to four existing assays were performed: (1) radioimmunoprecipitation assay (RIPA), (2) flow cytometric internalisation assay (FCIA), (3) cell-based assay (CBA-1) where HEK293T cells were transfected with α3β4 gnACHR subunits and (4) optimised CBA-2 with additional transfection of RIC3 and NACHO and incubation with 1 mM nicotine. The BLIA detected gnACHR antibodies with 100% sensitivity and 100% specificity (AUROC = 1.0) with detection of the internalising effects of antibodies to concentrations of < 0.1 pM. There was complete qualitative agreement with CBA-2 (Cohen’s kappa = 1). No statistical difference between these two assays and the RIPA, which had slightly lower sensitivity (98%) and specificity (95%), or the FCIA, which had slightly reduced specificity (95%), was found. CBA-1 had significantly lower sensitivity (69%, p = 0.0003). Overall, the BLIA had perfect clinical sensitivity and specificity in detecting gnACHR antibodies in AAG patients and detection of the functional effects of gnACHR antibodies via internalisation offers a suitable alternative to current assays. Further assessment of its possible role in monitoring disease severity or treatment response is warranted. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s40478-026-02386-9.
SN - 2051-5960
ER -